Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 30 versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 30 versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
CONRAY 30 vs DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, providing vascular and organ opacification. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
Intravenous: 50-300 mL of a 30% solution (150-900 mg iodine/kg) as a single dose for contrast enhancement. Dosing depends on procedure and patient weight.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min)
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Renal (90-100% unchanged via glomerular filtration within 24 hours); minimal biliary/fecal (<1%)
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent